Search bioRxiv⌕ Search

Biology subjects

Crawford, F.

Publications and source records attributed to Crawford, F..

5 recordsLinked to original sources

Perturbation-based propagation of bacterial composition uncertainty improves robustness and reproducibility of microbiome differential abundance analysis.

Differential abundance (DA) analysis remains the analytical bottleneck of microbiome science; despite dozens of available methods, results remain poorly reproducible across tools, datasets, and study designs. Three intertwined challenges drive this failure: compositional data structure, stochastic count uncertainty, and complex experimental design; yet no existing method addresses all three simultaneously. Here, we introduce PARALLAX (Perturbation-based Assessment of Robustness Across Latent Logical Axes), a unified DA framework that resolves this gap by propagating compositional uncertainty through per-replicate linear mixed modeling across a structured scale perturbation grid, then summarizes inference through two stability-based metrics: Ppost (effect consistency across Monte Carlo replicates) and Rscale (robustness to scale perturbation). PARALLAX retains uncertainty through the complete inferential pipeline while natively supporting repeated measures and multifactorial designs. Under repeated subsampling, PARALLAX identified fully stable DA taxa in 14.4% of cases, versus 1.7% and 0% for comparators. We applied PARALLAX to two independent longitudinal shotgun metagenomic datasets from mechanistically distinct mouse models: Gulf War toxicant exposure and repetitive head trauma. In both, PARALLAX resolved robust, sex-specific, and time-dependent genus-level shifts while accommodating repeated measures and multifactorial design, tasks that challenged both comparator frameworks. PARALLAX is released as an open-source, AI-compatible R workflow, lowering the barrier to rigorous microbiome DA analysis across complex study designs.

bioinformatics↗

The NOX2-ROS-NLRP3 inflammasome axis in traumatic brain injury

BackgroundPhagocyte NADPH oxidase 2 (NOX2) is an enzyme complex responsible for reactive oxygen species (ROS) production. Chronic NOX2 activity sustains oxidative stress/damage and drives neuroinflammation following traumatic brain injury (TBI). NOX2 acts as a priming signal for NLRP3 inflammasome activation, which also plays a role in secondary injury after TBI. GSK2795039 is a small molecule brain penetrable drug that inhibits NOX2 in a NADPH competitive manner. Here, we investigated whether pharmacological inhibition of NOX2 using GSK2795039 can reduce secondary neuroinflammation after TBI, specifically via inhibition of downstream NLRP3 inflammasome activation, in both resident microglia and infiltrating myeloid cells in the injured brain. MethodsImmortalised microglial (IMG) cells or primary microglia were pre-treated with GSK2795039 (NOX2 inhibitor) or MCC950 (NLRP3 inhibitor) and stimulated with lipopolysaccharide and nigericin to induce NOX2/ROS and NLRP3 inflammasome activation. The controlled cortical impact model, pharmacokinetic analyses, multi-dimensional flow cytometry, histology and neurobehavioral assessments were used to translate in vitro findings to an experimental TBI model in adult male C57BL6/J mice. ResultsThe small molecule NOX2 inhibitor, GSK2795039, attenuated microglial NOX2 activity, thereby reducing ROS, nitrite and cytokine levels, as well as NLRP3 inflammasome components in pro-inflammatory microglia. TBI recruited NOX2/ROS/IL-1{beta}+ neutrophils and inflammatory monocytes into injured brain parenchyma with peak monocytic NOX2/ROS/IL-1{beta} production at 3 days post-injury (DPI), coincident with peak NOX2/ROS/IL-1{beta} expression in microglia. Systemic administration of GSK2795039 (100mg/kg; I.P.) starting 2 hours post-injury attenuated NOX2/IL-1{beta}+ microglial and infiltrating myeloid cell activation at 3 DPI. In addition, NOX2 inhibition reduced numbers of IL-1R+ T cells in the brain of TBI mice, indicating that myeloid-T cell crosstalk was altered by GSK2795039 treatment. Innate and adaptive neuroimmune changes were associated with improvements in motor function post-TBI. In the chronic phase through 28 DPI, pharmacological inhibition of NOX2 by GSK2795039 treatment resulted in modest improvements in neurobehavioral deficits and TBI neuropathology. ConclusionsThese preclinical studies identify the NOX2-ROS-NLRP3 inflammasome axis along with myeloid-T cell crosstalk as effective targets for TBI neuroinflammation. Our translational studies indicate that NOX2 may be a promising therapeutic target for mitigating neuroinflammation in microglia, and peripheral immune cells, following experimental TBI in mice.

neuroscience↗

Reading Outside the Lines: A Systematic Approach for Detecting Bias in Scientific Communication

Consciousness of the social impact of science and the potential biases of its authors is critical to understanding, interpreting, and using scientific findings responsibly. This is especially true for sciences concerned with human health and behavior, where societal and unconscious biases may reinforce existing inequities and discriminatory practices. Considering backgrounds and biases, we may notice bias influencing scientists methodological choices and conclusions, even when a work is otherwise scientifically sound. To this end, we created the pedagogical tool Finding inEquity in LIterature and eXperimentation (FELIX). FELIX is a tool that systematizes the detection of bias and subjectivity in scientific communications by using a three-phase progression of (i) Annotation, (ii) Analysis and (iii) Synthesis, where students form a unified argument about the text with a focus on its relationship to social or ethical context. Results from a mixed methods approach indicated the efficacy of our approach in supporting student learning related to reading comprehension, critical thinking skills, and in understanding the social and ethical implications of the research they were reading. We put forward FELIX as a universal method for training students in the reading of scientific communications and as a tool for addressing systemic inequities in science and science education.

scientific communication and education↗

JMJD6 Cleaves MePCE to Release P-TEFb

More than 30% of genes in higher eukaryotes are regulated by promoter-proximal pausing of RNA polymerase II (Pol II). Phosphorylation of Pol II-CTD by positive transcription elongation factor (P-TEFb) is a necessary precursor event that enables productive transcription elongation. The exact mechanism on how the sequestered P-TEFb is released from the 7SK snRNP complex and recruited to Pol II-CTD remains unknown. In this report, we reveal methylphosphate capping enzyme (MePCE), a core component of the 7SK snRNP complex, as the cognate substrate for Jumonji domain-containing 6 (JMJD6)s novel proteolytic function. Our evidences consist of a crystal structure of JMJD6 bound to methyl-arginine, enzymatic assays of JMJD6 cleaving MePCE in vivo and in vitro, binding assays, and downstream effects of Jmjd6 knockout and overexpression on Pol II-CTD phosphorylation. We propose that JMJD6 assists bromodomain containing 4 (BRD4) to recruit P-TEFb to Pol II-CTD by disrupting the 7SK snRNP complex.

biochemistry↗

Exploratory analyses suggest less cognitive decline on nilvadipine treatment in very mild Alzheimer’s disease subjects

BackgroundWe explored whether the effects of nilvadipine on cognition were influenced by baseline Alzheimers disease (AD) severity.\n\nMethodsExploratory analyses were performed on the modified intention-to-treat (mITT) dataset (n = 497) of a phase III randomized placebo-controlled trial to examine the response to nilvadipine in very mild, mild and moderate AD subjects. The outcome measures included total and subscale scores of the Alzheimers Disease Assessment Scale Cognitive 12 (ADAS-Cog 12), the Clinical Dementia Rating Scale sum of boxes (CDR-sb) and the AD composite score (ADCOMS), an outcome measure recently developed to detect treatment responses in subjects with prodromal AD. Cerebrospinal fluid (CSF) biomarkers A{beta}38, A{beta}40, A{beta}42, total tau and P181 tau were measured in a subset of samples (n = 55). Regression analyses were adjusted for potential confounders and effect modifiers in order to examine the interactive effects of nilvadipine and AD severity on cognitive outcomes over 78-weeks.\n\nResultsCompared to their respective placebo-controls, nilvadipine-treated, very mild AD subjects showed less decline, whereas moderate AD subjects showed greater decline on the ADAS-Cog 12. Also in very mild AD, a beneficial effect (as measured by ADCOMS), was detected in the nilvadipine treated group. Therapeutic effects of nilvadipine were also observed for a composite memory trait in very mild AD subjects and a composite language trait in mild AD subjects. CSF A{beta}42/A{beta}40 ratios were increased in mild AD and decreased in moderate AD patients treated with nilvadipine, compared to their respective controls.\n\nConclusionThese data suggest that very mild AD subjects benefited from nilvadipine and that future clinical trials of nilvadipine in this population are required to confirm these findings.\n\nTrial RegistrationNCT02017340 Registered 20 December 2013, https://clinicaltrials.gov/ct2/show/NCT02017340\n\nEUDRACT Reference Number 2012-002764-27 Registered 04 February 2013, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002764-27

clinical trials↗